Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00601718 · OUTCOME

Maximum Tolerated Dose of Vorinostat

Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma · Source last updated 2017-05-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
mg twice daily X 5 days
Interval / dispersion
Not reported
Time frame
28 days post last dose of study drug

Groups in this outcome

Treatment (Enzyme Inhibitor, Monoclonal Antibody, Chemotherapy

Patients receive vorinostat PO QD on days 1-5, ifosfamide IV continuously over 24 hours and carboplatin IV over 1 hour on day 4, and etoposide IV over 1 hour on days 3-5. Patients who are CD20+ also receive rituximab IV once on day 3, 4, or 5. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. vorinostat: Given PO rituximab: Given IV ifosfamide: Given IV carboplatin: Given IV etoposide: Given IV pharmacological study: Correlative studies laboratory biomarker analysis: Correlative studies gene expression analysis: Correlative studies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Enzyme Inhibitor, Monoclonal Antibody, Chemotherapy29

Reported measurements

Source class 1
Values in mg twice daily X 5 days · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Enzyme Inhibitor, Monoclonal Antibody, Chemotherapy500Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        500
denoms
  1. counts
    1. group Id
      OG000
      value
      29
    units
    Participants
groups
  1. description
    Patients receive vorinostat PO QD on days 1-5, ifosfamide IV continuously over 24 hours and carboplatin IV over 1 hour on day 4, and etoposide IV over 1 hour on days 3-5. Patients who are CD20+ also receive rituximab IV once on day 3, 4, or 5. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. vorinostat: Given PO rituximab: Given IV ifosfamide: Given IV carboplatin: Given IV etoposide: Given IV pharmacological study: Correlative studies laboratory biomarker analysis: Correlative studies gene expression analysis: Correlative studies
    id
    OG000
    title
    Treatment (Enzyme Inhibitor, Monoclonal Antibody, Chemotherapy
param Type
NUMBER
reporting Status
POSTED
time Frame
28 days post last dose of study drug
title
Maximum Tolerated Dose of Vorinostat
type
PRIMARY
unit Of Measure
mg twice daily X 5 days

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice